(RTTNews) – What moves those in the hours leading up to the market today?
In the green
1. Immunic Inc. (IMUX) has risen more than 29% to $22.31 in pre-trade on Monday, following a high-level positive knowledge of the Phase II trial of its main asset, IMU-838, in patients with recurrent-sender sclerosis, nicknamed EMPASIS.
2. Varian Medical Systems Inc. (VAR) has risen more than 23% to $176 in pre-marketing today, and the corporate will be acquired through the German health care organization Siemens Healthineers AG for approximately $16.4 billion.
4. Trevena Inc. (TRVN) has risen more than 12% to $2.60 in pre-market hours today. The FDA’s ruling on olycerridine, an intravenous pain reliever, for moderate to severe acute pain management is expected by August 7.
In the red
1. VistaGen Therapeutics Inc. (VTGN) dropped by 17% to $0.77 in pre-marketing operations, following the value of its underwritten public offering of 15.63 million non-unusual shares to $0.80 each. The gross source is expected to be $12.5 million. The subscriber has a 45-day option to acquire up to 2.34 million more non-unusual shares of the company.
2. ADMA Biologics Inc. (ADMA), a commercially developed corporation that is emerging plasma derivatives for the prevention and remedy of infectious diseases, has fallen more than 6% to $3.35 in pre-marketing today. The corporate is expected to publish its quarterly monetary effects on August 5.
4. electroCore Inc. (ECOR) has fallen 8% in pre-market trading today, returning some of what it earned on Friday. On Friday, inventory closed at $2.23, up 44%, following an update on the availability, distribution and costs of the gammaCore Sapphire CV noninvasive nerve stimulation cure. As a component of emergency use authorization, gammaCore Sapphire CV has been legal to be used at home or at a health center for the acute treatment of asthma exacerbations in patients with known or suspected COVID-19.